Incomplete Cancer Surgery Correlates With Loss of Immune Surveillance and Hyper-Progression of Disease

By afschroeder • July 10, 2025

Fine SA, Lim SY, Siena NM, de Jesus AB, Goh T, Markus L, Russell TA, Kendal JK, Lofftus SY, Shehata MS, Dao HB, Lee A, Klingbeil KD, Kadera BE, Chmielowski B, Nelson SD, Dry SM, Bernthal NM, Singh AS, Reddy VK, Kalbasi A, Wessel LE, Prins RM, Eilber FR, Eilber FC, McCaw TR, Crompton JG. Incomplete Cancer Surgery Correlates With Loss of Immune Surveillance and Hyper-Progression of Disease. J Surg Oncol. 2025 Jul 9. doi: 10.1002/jso.70023. Epub ahead of print. PMID: 40631605.

Tags: Hematology/Oncology, hyper‐progression, immunosuppression, myeloid‐derived suppressor cell, oncologic surgery, Publications, regulatory T cell, soft tissue sarcoma, tumor microenvironment

SGNDV-001: disitamab vedotin with pembrolizumab in HER2-expressing locally advanced or metastatic urothelial carcinoma

Powles TB, Grande E, Alimohamed N, Oliveira N, Sridhar SS, Drakaki A, Kanesvaran R, Loriot Y, Necchi A, Franco S, Jiang D, Apolinario K, Zhang[...]

Revolutionizing breast cancer treatment: the promise of antibody-drug conjugates

Alkassis S, Glaspy JA, Bardia A. Revolutionizing breast cancer treatment: the promise of antibody-drug conjugates. Clin Adv Hematol Oncol. 2025 Jul-Aug;23(5):290-299. PMID: 40728347.

A Patient’s Journey With Modern Melanoma Therapy

Black AC, Senofsky G. A Patient's Journey With Modern Melanoma Therapy. Cureus. 2025 Jun 26;17(6):e86811. doi: 10.7759/cureus.86811. PMID: 40718227; PMCID: PMC12296936.